Survival following HIV infection of a cohort followed up from seroconversion in the UK
- 2 January 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 22 (1), 89-95
- https://doi.org/10.1097/qad.0b013e3282f3915e
Abstract
To estimate changes over calendar time in survival following HIV seroconversion in the era of HAART and to provide updated survival estimates. Using data from a UK cohort of persons with well estimated dates of HIV seroconversion, we analysed time from seroconversion to death from any cause using Cox models, adjusted for prognostic factors. Kaplan-Meier methods were then used to determine the expected survival in each calendar period. 2275 seroconverters were included with 18 695 person-years of follow up. A total of 444 (20%) died. The relative risk of death, compared with pre-1996, decreased over time to 0.63 [95% confidence interval (CI), 0.48-0.81], 0.24 (0.17-0.34), 0.14 (0.10-0.21), 0.08 (0.05-0.13) and 0.03 (0.02-0.06) in 1996-1997, 1998-1999, 2000-2001, 2002-2003 and 2004-2006, respectively. An elevated risk of death was associated with older age at seroconversion [hazard ratio (HR), 1.49; 95% CI, 1.34-1.66 per 10-year increase] and HIV infection through injecting drug use (HR, 1.53; 95% CI, 1.17-2.00). In 2000-2006, the proportion of individuals expected to survive 5, 10 and 15 years following seroconversion was 99%, 94% and 89%, respectively. Survival following HIV seroconversion has continued to improve over calendar time in our cohort, even in the more recent years of HAART availability. HIV seroconverters, by definition identified early in their infection, are likely to have the greatest opportunity for intervention; if similar high survival expectations are to be seen in the wider HIV-infected population, early diagnosis is likely to be crucial.Keywords
This publication has 18 references indexed in Scilit:
- Survival of Persons with and without HIV Infection in Denmark, 1995–2005Annals of Internal Medicine, 2007
- HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general populationScandinavian Journal of Infectious Diseases, 2007
- The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004)AIDS, 2006
- HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisThe Lancet, 2006
- Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral TherapyArchives of Internal Medicine, 2006
- Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes onAIDS, 2006
- Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markersAIDS, 2006
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- The relationship between HIV seroconversion illness, HIV test interval and time to AIDS in a seroconverter cohortEpidemiology and Infection, 2003
- The UK Register of HIV Seroconverters: methods and analytical issuesEpidemiology and Infection, 1996